3 terminated, 2 recruiting. 3 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 2, Recruiting 1 |
| Phase 3 | 3 | Terminated 2, Recruiting 1 |
Follow Elgan Pharma Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA ELGN-2112, Placebo - Intestinal Malabsorption | Phase 2 | Recruiting | Elgan Pharma Ltd. | 60 | 2025-10-28 | 2026-04-09 |
| Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants ELGN-2112, Placebo - Intestinal Malabsorption | Phase 3 | Recruiting | Elgan Pharma Ltd. | 360 | 2025-02-27 | 2026-01-23 |
| Safety and Efficacy Study in Infant With SBS NTRA-9620, Placebo - Short Bowel Syndrome | Phase 2 / Phase 3 | Terminated | Elgan Pharma Ltd. | 2 | 2017-03-20 | 2021-10-12 |
| Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants NTRA-2112, Placebo - Premature Birth of Newborn, Intestinal Malabsorption | Phase 3 | Terminated | Elgan Pharma Ltd. | 300 | 2016-10-09 | 2025-08-19 |
| Oral Formulation of Insulin for Preterm Infants Oral Formulation of Insulin, Placebo - Premature Birth of Newborn | Phase 2 | Terminated | Elgan Pharma Ltd. | 33 | 2010-08-01 | 2021-03-18 |
Malabsorption Syndromes (3) · Premature Birth (2) · Short Bowel Syndrome (1)
Israel (4) · United States (2) · Belgium (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Netherlands (1) · Spain (1) · United Kingdom (1)
Miki Olshansky (1) · Naim Shehadeh, Prof. (1)